Celgene Corporation - Recruiting 18 years or older. - A Phase 1a/b, Multicenter, Open Label, Dose-Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the Dual DNA-PK and TOR Kinase Inhibitor, CC-115, Administered Orally to Subjects With Advanced Solid Tumors, and Hematologic Malignancies..
Duke University - Recruiting 18 years or older. - REGULATory T-Cell Inhibition With Basiliximab (Simulectr) During Recovery From Therapeutic Temozolomide-induced Lymphopenia During Antitumor Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed Glioblastoma Multiforme.
Technische Universitt Dresden - Recruiting 18 years or older. - Observational Study of Impact of [11C]-Methionine PET/MRI as a Tool for Individual Tailoring Postoperative Radiochemotherapy for Patients With Glioblastoma Multiforme.
CytoVac A/S - Recruiting 18 years or older. - An Open-labelled, Randomized Phase II Multicentre Study to Investigate Efficacy of Autologous Lymphoid Effector Cells Specific Against Tumour-Cells (ALECSAT) in Patients With Glioblastoma Multiforme Measured as Progression Free Survival Compared to Avastin/Irinotecan.
Washington University School of Medicine - Recruiting 18 years or older. - A Pilot Study of Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Doxorubicin in the Treatment of Recurrent Glioblastoma Multiforme.
Amgen - Recruiting 18 years or older. - A Phase 1 First-in-Human Study Evaluating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 595 in Subjects With Recurrent Malignant Glioma Expressing Mutant Epidermal Growth Factor Receptor Variant III (EGFRvIII).
Cortice Biosciences, Inc. - Recruiting 18 years or older. - Phase 2 Dose-Escalation Study of TPI 287 in Combination With Bevacizumab in Adults With Recurrent or Progressive Glioblastoma Following Bevacizumab Alone.
Tocagen Inc. - Recruiting 18 years to 80 years. - A P1 Ascending Dose Trial of the Safety and Tolerability of Toca 511, a Retroviral Replicating Vector, Administered Intravenously Prior to, and Intracranially at the Time of, Subsequent Resection for Recurrent HGG & Followed by Treatment With Extended-Release 5-FC.
National Cancer Institute (NCI) - Recruiting 18 years or older. - Phase I/Comparative Randomized Phase II Trial of TRC105 Plus Bevacizumab Versus Bevacizumab in Bevacizumab-Nave Patients With Recurrent Glioblastoma Multiforme.
anti-endoglin monoclonal antibody TRC105; bevacizumab; laboratory biomarker analysis; pharmacological study
SCRI Development Innovations, LLC - Recruiting 18 years or older. - Phase I/II Study of the Combination of BKM120 and Bevacizumab in Patients With Refractory Solid Tumors (Phase I) and Relapsed/Refractory Glioblastoma Multiforme (Phase II).
M.D. Anderson Cancer Center - Recruiting 18 years or older. - A Phase I lead-in to a 2x2x2 Factorial Trial of Dose Dense Temozolomide, Memantine, Mefloquine, and Metformin As Post-Radiation Adjuvant Therapy of Glioblastoma Multiforme.
AbbVie - Recruiting 18 years or older. - A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-414 in Combination With Radiation Plus Temozolomide or Temozolomide Alone for Subjects With Glioblastoma Multiforme.
Medical University of South Carolina - Recruiting 18 years to 80 years. - Imaging Biomarkers of Tissue Microstructure and Vasculature as Predictors of Glioblastoma Multiforme Response to Treatment With Bevacizumab for Progressive Disease.
National Cancer Institute (NCI) - Recruiting 18 years or older. - Phase I/Randomized Phase II Trial of Either Dasatinib or Placebo Combined With Standard Chemo-Radiotherapy for Newly Diagnosed Glioblastoma Multiforme (GBM).
Weill Medical College of Cornell University - Recruiting 18 years or older. - Phase I Trial of Super-Selective Intraarterial Intracranial Infusion of Avastin (Bevacizumab) For Treatment of Relapsed/Refractory Glioblastoma Multiforme and Anaplastic Astrocytoma.
Super-Selective Intraarterial Intracranial Infusion of BEVACIZUMAB
Weill Medical College of Cornell University - Recruiting 18 years or older. - Phase I/II Trial Of Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory Glioblastoma Multiforme And Anaplastic Astrocytoma.
Northern Sydney and Central Coast Area Health Service - Recruiting 18 years or older. - Phase 11 Study of Cilengitide in Combination With Concurrent Chemotherapy and Radiotherapy Followed by Protracted Daily Low Dose Temozolomide and Low Dose Procarbazine D1 - 20 in Newly Diagnosed Glioblastoma Without Methylation of the MGMT Promoter Gene.